Case Control Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. May 15, 2024; 16(5): 1737-1744
Published online May 15, 2024. doi: 10.4251/wjgo.v16.i5.1737
Evaluation of the value of combined detection of tumor markers CA724, carcinoembryonic antigen, CA242, and CA19-9 in gastric cancer
Chong-Mei Zhou, Shao-Hua Zhao
Chong-Mei Zhou, Shao-Hua Zhao, Department of Clinical Laboratory, Henan Provincial People's Hospital, Zhengzhou 450003, Henan Province, China
Author contributions: Zhou CM designed the research study; Zhao SH performed the research; Zhou CM and Zhao SH contributed new reagents and analytical tools; Zhou CM analyzed the data and wrote the manuscript; all authors have read and approved the final version of the manuscript.
Institutional review board statement: The study was reviewed and approved by the Science and Research Office of Henan Provincial People’s Hospital (Henan).
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: There are no conflicts of interest to report.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chong-Mei Zhou, Doctor, Master's Student, Department of Clinical Laboratory, Henan Provincial People’s Hospital, No. 38 Nongke Road, Jinshui District, Zhengzhou 450003, Henan Province, China. vlm010o@163.com
Received: January 12, 2024
Peer-review started: January 12, 2024
First decision: January 30, 2024
Revised: February 8, 2024
Accepted: March 20, 2024
Article in press: March 20, 2024
Published online: May 15, 2024
Processing time: 118 Days and 10.2 Hours
Abstract
BACKGROUND

Gastric cancer is a global health concern that poses a significant threat to human well-being.

AIM

To detecting serum changes in carcinoembryonic antigen (CEA), carbohydrate antigens (CA) 724, CA242, and CA19-9 expression among patients with gastric cancer.

METHODS

Eighty patients diagnosed with gastric cancer between January 2020 and January 2023 were included in the observation group, while 80 patients with benign gastric diseases were included in the control group. Both groups were tested for tumor markers (CA724, CEA, CA242, and CA19-9]. Tumor marker indicators (CA724, CEA, CA242, and CA19-9) were compared between the two groups, assessing positive rates of tumor markers across various stages in the observation group. Additionally, single and combined detection of various tumor markers were examined.

RESULTS

The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value observed for the combined detection of CA724, CEA, CA242, and CA19-9 were higher than those of CA724, CEA, CA242, and CA19-9 individually. Therefore, the combined detection of CA724, CEA, CA242, and CA19-9 has a high diagnostic accuracy and could reduce the occurrence of missed or misdiagnosed cases, facilitating the early diagnosis and treatment of patients.

CONCLUSION

CA724, CEA, CA242, and CA19-9 serum levels in gastric cancer patients significantly surpassed those in non-gastric cancer patients (P < 0.05). Their combined detection can improve the diagnostic accuracy for gastric cancer, warranting clinical promotion.

Keywords: Biomarkers; Serum; Gastric cancer; Diagnostic value

Core Tip: This study provides a theoretical basis for clinical screening programs for patients with gastric cancer. In the future, the combined detection of carbohydrate antigens (CA) 724, carcinoembryonic antigen, CA242, and CA19-9 could complement the clinical diagnosis.